Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Everplay FY results seen 'slightly ahead' of expectations

(Sharecast News) - Games developer Everplay Group said on Wednesday that its FY results seen "slightly ahead" of current expectations after it traded strongly across H125, with new game releases performing positively. Everplay said its recently launched Date Everything! title has been "particularly well received", with excellent sales, concurrent users and review scores to date. It's Sworn and Nice Day for Fishing titles were also said to have delivered "encouraging starts" since launch.

As a result of its H1 performance, Everplay said the "continued robust performance" from its back catalogue and "positive momentum" going into H2, it now expects FY results to be "slightly ahead" of current market expectations.

The London-listed firm also noted that, as in previous years, adjusted underlying earnings were expected to be H2-weighted, due to the timing of new game releases.

Everplay expects to announce its interim results in early September.

As of 0900 BST, Everplay shares were up 9.91% at 344.01p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.